{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,13]],"date-time":"2026-03-13T12:32:38Z","timestamp":1773405158178,"version":"3.50.1"},"reference-count":46,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2017,1,1]],"date-time":"2017-01-01T00:00:00Z","timestamp":1483228800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"funder":[{"DOI":"10.13039\/100009671","name":"ACHRI","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100009671","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100008231","name":"Arkansas Biosciences Institute","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100008231","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["R01DK055653"],"award-info":[{"award-number":["R01DK055653"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["R21AR070620"],"award-info":[{"award-number":["R21AR070620"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["C06RR16517"],"award-info":[{"award-number":["C06RR16517"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000738","name":"Department of Veterans Affairs","doi-asserted-by":"crossref","id":[{"id":"10.13039\/100000738","id-type":"DOI","asserted-by":"crossref"}]},{"DOI":"10.13039\/100007217","name":"Veterans Health Administration","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100007217","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100006379","name":"Office of Research and Development","doi-asserted-by":"publisher","award":["1I01BX001018"],"award-info":[{"award-number":["1I01BX001018"]}],"id":[{"id":"10.13039\/100006379","id-type":"DOI","asserted-by":"publisher"}]},{"name":"University of Kentucky Barnstable Brown Diabetes Center Endowment"}],"content-domain":{"domain":["clinicalkey.jp","thebonejournal.com","clinicalkey.com","clinicalkey.es","clinicalkey.fr","clinicalkey.com.au","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Bone"],"published-print":{"date-parts":[[2017,1]]},"DOI":"10.1016\/j.bone.2016.10.026","type":"journal-article","created":{"date-parts":[[2016,10,28]],"date-time":"2016-10-28T08:30:49Z","timestamp":1477643449000},"page":"141-151","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":58,"special_numbering":"C","title":["The impact of SGLT2 inhibitors, compared with insulin, on diabetic bone disease in a mouse model of type 1 diabetes"],"prefix":"10.1016","volume":"94","author":[{"given":"Kathryn M.","family":"Thrailkill","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jeffry S.","family":"Nyman","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"R. Clay","family":"Bunn","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sasidhar","family":"Uppuganti","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Katherine L.","family":"Thompson","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"suffix":"Jr","given":"Charles K.","family":"Lumpkin","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0556-3975","authenticated-orcid":false,"given":"Evangelia","family":"Kalaitzoglou","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"John L.","family":"Fowlkes","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.bone.2016.10.026_bb0005","series-title":"Diabetic Bone Disease","year":"2016"},{"issue":"10","key":"10.1016\/j.bone.2016.10.026_bb0010","doi-asserted-by":"crossref","first-page":"2217","DOI":"10.2337\/dc10-0612","article-title":"Dapagliflozin monotherapy in type 2 diabetic patients with inadequate glycemic control by diet and exercise: a randomized, double-blind, placebo-controlled, phase 3 trial","volume":"33","author":"Ferrannini","year":"2010","journal-title":"Diabetes Care"},{"key":"10.1016\/j.bone.2016.10.026_bb0015","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1186\/1475-2840-13-65","volume":"13","author":"Kaku","year":"2014","journal-title":"Cardiovasc. Diabetol."},{"issue":"6","key":"10.1016\/j.bone.2016.10.026_bb0020","doi-asserted-by":"crossref","first-page":"405","DOI":"10.7326\/0003-4819-156-6-201203200-00003","article-title":"Dapagliflozin 006 study G. Long-term efficacy of dapagliflozin in patients with type 2 diabetes mellitus receiving high doses of insulin: A randomized trial","volume":"156","author":"Wilding","year":"2012","journal-title":"Ann. Intern. Med."},{"issue":"7","key":"10.1016\/j.bone.2016.10.026_bb0025","doi-asserted-by":"crossref","first-page":"1815","DOI":"10.2337\/dc13-3055","article-title":"Improved glucose control with weight loss, lower insulin doses, and no increased hypoglycemia with empagliflozin added to titrated multiple daily injections of insulin in obese inadequately controlled type 2 diabetes","volume":"37","author":"Rosenstock","year":"2014","journal-title":"Diabetes Care"},{"issue":"3","key":"10.1016\/j.bone.2016.10.026_bb0030","doi-asserted-by":"crossref","first-page":"384","DOI":"10.2337\/dc14-2364","article-title":"Combination of empagliflozin and linagliptin as second-line therapy in subjects with type 2 diabetes inadequately controlled on metformin","volume":"38","author":"DeFronzo","year":"2015","journal-title":"Diabetes Care"},{"issue":"5","key":"10.1016\/j.bone.2016.10.026_bb0035","doi-asserted-by":"crossref","first-page":"463","DOI":"10.1080\/00325481.2015.1044756","article-title":"Clinical use of dipeptidyl peptidase-4 and sodium-glucose cotransporter 2 inhibitors in combination therapy for type 2 diabetes mellitus","volume":"127","author":"Guthrie","year":"2015","journal-title":"Postgrad. Med."},{"key":"10.1016\/j.bone.2016.10.026_bb0040","doi-asserted-by":"crossref","DOI":"10.1016\/j.clinthera.2015.05.511","article-title":"Empagliflozin as Add-on Therapy to Pioglitazone With or Without Metformin in Patients With Type 2 Diabetes Mellitus","author":"Kovacs","year":"2015","journal-title":"Clin. Ther."},{"key":"10.1016\/j.bone.2016.10.026_bb0045","doi-asserted-by":"crossref","DOI":"10.2337\/dc15-0779","article-title":"A randomized, double-blind, phase 3 trial of triple therapy with dapagliflozin add-on to Saxagliptin plus metformin in type 2 diabetes","author":"Mathieu","year":"2015","journal-title":"Diabetes Care"},{"issue":"5","key":"10.1016\/j.bone.2016.10.026_bb0050","doi-asserted-by":"crossref","first-page":"1480","DOI":"10.2337\/dc13-2338","article-title":"Sodium-glucose cotransporter 2 inhibition and glycemic control in type 1 diabetes: Results of an 8-week open-label proof-of-concept trial","volume":"37","author":"Perkins","year":"2014","journal-title":"Diabetes Care"},{"key":"10.1016\/j.bone.2016.10.026_bb0055","first-page":"676191","article-title":"Case reports that illustrate the efficacy of SGLT2 inhibitors in the type 1 diabetic patient","volume":"2015","author":"Bell","year":"2015","journal-title":"Case Rep. Endocrinol."},{"issue":"9","key":"10.1016\/j.bone.2016.10.026_bb0060","doi-asserted-by":"crossref","first-page":"1687","DOI":"10.2337\/dc15-0843","article-title":"Euglycemic diabetic ketoacidosis: A potential complication of treatment with sodium-glucose cotransporter 2 inhibition","volume":"38","author":"Peters","year":"2015","journal-title":"Diabetes Care"},{"key":"10.1016\/j.bone.2016.10.026_bb0065","doi-asserted-by":"crossref","DOI":"10.2337\/dc14-2806","article-title":"Sotagliflozin, a dual SGLT1 and SGLT2 inhibitor, as adjunct therapy to insulin in type 1 diabetes","author":"Sands","year":"2015","journal-title":"Diabetes Care"},{"issue":"5","key":"10.1016\/j.bone.2016.10.026_bb0070","doi-asserted-by":"crossref","first-page":"520","DOI":"10.1038\/clpt.2008.251","article-title":"Dapagliflozin, a novel SGLT2 inhibitor, induces dose-dependent glucosuria in healthy subjects","volume":"85","author":"Komoroski","year":"2009","journal-title":"Clin. Pharmacol. Ther."},{"issue":"7","key":"10.1016\/j.bone.2016.10.026_bb0075","doi-asserted-by":"crossref","first-page":"669","DOI":"10.1111\/j.1463-1326.2011.01406.x","article-title":"Canagliflozin, a novel inhibitor of sodium glucose co-transporter 2, dose dependently reduces calculated renal threshold for glucose excretion and increases urinary glucose excretion in healthy subjects","volume":"13","author":"Sha","year":"2011","journal-title":"Diabetes Obes. Metab."},{"issue":"11","key":"10.1016\/j.bone.2016.10.026_bb0080","doi-asserted-by":"crossref","first-page":"1111","DOI":"10.1111\/dom.12327","article-title":"Durability of glycaemic efficacy over 2years with dapagliflozin versus glipizide as add-on therapies in patients whose type 2 diabetes mellitus is inadequately controlled with metformin","volume":"16","author":"Nauck","year":"2014","journal-title":"Diabetes Obes. Metab."},{"key":"10.1016\/j.bone.2016.10.026_bb0085","doi-asserted-by":"crossref","DOI":"10.1152\/ajprenal.00267.2015","article-title":"Renal Sodium-Glucose Cotransporter Inhibition in the Management of Type 2 Diabetes Mellitus","author":"Abdul-Ghani","year":"2015","journal-title":"Am. J. Physiol. Ren. Physiol."},{"issue":"1","key":"10.1016\/j.bone.2016.10.026_bb0090","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1016\/S2213-8587(14)70227-X","article-title":"Possible adverse effects of SGLT2 inhibitors on bone","volume":"3","author":"Taylor","year":"2015","journal-title":"Lancet Diabetes Endocrinol."},{"issue":"4","key":"10.1016\/j.bone.2016.10.026_bb0095","doi-asserted-by":"crossref","first-page":"962","DOI":"10.1038\/ki.2013.356","article-title":"Long-term study of patients with type 2 diabetes and moderate renal impairment shows that dapagliflozin reduces weight and blood pressure but does not improve glycemic control","volume":"85","author":"Kohan","year":"2014","journal-title":"Kidney Int."},{"issue":"1","key":"10.1016\/j.bone.2016.10.026_bb0100","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1016\/0168-8227(94)90126-0","article-title":"Osteopenia associated with non-insulin-dependent diabetes mellitus: What are the causes?","volume":"23","author":"Gregorio","year":"1994","journal-title":"Diabetes Res. Clin. Pract."},{"key":"10.1016\/j.bone.2016.10.026_bb0105","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1016\/j.bone.2015.07.025","article-title":"SGLT2 inhibitor therapy improves blood glucose but does not prevent diabetic bone disease in diabetic DBA\/2J male mice","volume":"82","author":"Thrailkill","year":"2016","journal-title":"Bone"},{"key":"10.1016\/j.bone.2016.10.026_bb0110","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1016\/j.bonr.2014.10.001","article-title":"Effects of long-term doxycycline on bone quality and strength in diabetic male DBA\/2J mice","volume":"1","author":"Fowlkes","year":"2015","journal-title":"Bone Rep."},{"key":"10.1016\/j.bone.2016.10.026_bb0115","doi-asserted-by":"crossref","first-page":"220","DOI":"10.1016\/j.bone.2015.11.009","article-title":"Age-related changes in the fracture resistance of male Fischer F344 rat bone","volume":"83","author":"Uppuganti","year":"2016","journal-title":"Bone"},{"issue":"46","key":"10.1016\/j.bone.2016.10.026_bb0120","doi-asserted-by":"crossref","first-page":"44005","DOI":"10.1074\/jbc.M208265200","article-title":"Osteoblast-specific knockout of the insulin-like growth factor (IGF) receptor gene reveals an essential role of IGF signaling in bone matrix mineralization","volume":"277","author":"Zhang","year":"2002","journal-title":"J. Biol. Chem."},{"issue":"9","key":"10.1016\/j.bone.2016.10.026_bb0125","doi-asserted-by":"crossref","first-page":"1040","DOI":"10.1016\/j.yexcr.2012.02.027","article-title":"Role of FGF23 in vitamin D and phosphate metabolism: implications in chronic kidney disease","volume":"318","author":"Quarles","year":"2012","journal-title":"Exp. Cell Res."},{"issue":"1","key":"10.1016\/j.bone.2016.10.026_bb0130","doi-asserted-by":"crossref","first-page":"289","DOI":"10.1111\/j.2517-6161.1995.tb02031.x","article-title":"Controlling the false discovery rate: a practical and powerful approach to multiple testing","volume":"57","author":"Benjamini","year":"1995","journal-title":"J. R. Stat. Soc."},{"issue":"10","key":"10.1016\/j.bone.2016.10.026_bb0135","doi-asserted-by":"crossref","first-page":"2875","DOI":"10.2337\/diabetes.54.10.2875","article-title":"Bone formation is impaired in a model of type 1 diabetes","volume":"54","author":"Thrailkill","year":"2005","journal-title":"Diabetes"},{"issue":"4","key":"10.1016\/j.bone.2016.10.026_bb0140","doi-asserted-by":"crossref","first-page":"733","DOI":"10.1016\/j.bone.2010.12.016","article-title":"Increasing duration of type 1 diabetes perturbs the strength-structure relationship and increases brittleness of bone","volume":"48","author":"Nyman","year":"2011","journal-title":"Bone"},{"key":"10.1016\/j.bone.2016.10.026_bb0145","series-title":"76th Scientific Sessions of the ADA","article-title":"Acute effects of canagliflozin on bone metabolism: Preliminary results from a randomized, placebo-controlled trial","year":"2016"},{"key":"10.1016\/j.bone.2016.10.026_bb0150","first-page":"1","article-title":"The Effects of Canagliflozin, a Sodium Glucose Co-transporter 2 Inhibitor, on Mineral Metabolism and Bone in Patients With Type 2 Diabetes Mellitus","author":"Alba","year":"2016","journal-title":"Curr. Med. Res. Opin."},{"issue":"4","key":"10.1016\/j.bone.2016.10.026_bb0155","doi-asserted-by":"crossref","first-page":"650","DOI":"10.2337\/dc08-1863","article-title":"Sodium-glucose cotransport inhibition with dapagliflozin in type 2 diabetes","volume":"32","author":"List","year":"2009","journal-title":"Diabetes Care"},{"issue":"1","key":"10.1016\/j.bone.2016.10.026_bb0160","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1210\/jc.2015-1860","article-title":"Evaluation of bone mineral density and bone biomarkers in patients with type 2 diabetes treated with canagliflozin","volume":"101","author":"Bilezikian","year":"2016","journal-title":"J. Clin. Endocrinol. Metab."},{"issue":"11","key":"10.1016\/j.bone.2016.10.026_bb0165","doi-asserted-by":"crossref","first-page":"990","DOI":"10.1111\/j.1463-1326.2012.01630.x","article-title":"Dapagliflozin has no effect on markers of bone formation and resorption or bone mineral density in patients with inadequately controlled type 2 diabetes mellitus on metformin","volume":"14","author":"Ljunggren","year":"2012","journal-title":"Diabetes Obes. Metab."},{"key":"10.1016\/j.bone.2016.10.026_bb0170","doi-asserted-by":"crossref","DOI":"10.1016\/j.clinthera.2016.03.031","article-title":"Safety and tolerability of empagliflozin in patients with type 2 diabetes","author":"Kohler","year":"2016","journal-title":"Clin. Ther."},{"issue":"7","key":"10.1016\/j.bone.2016.10.026_bb0175","doi-asserted-by":"crossref","first-page":"1576","DOI":"10.1016\/j.cell.2015.05.029","article-title":"Glucose uptake and Runx2 synergize to orchestrate osteoblast differentiation and bone formation","volume":"161","author":"Wei","year":"2015","journal-title":"Cell"},{"issue":"3","key":"10.1016\/j.bone.2016.10.026_bb0180","doi-asserted-by":"crossref","first-page":"789","DOI":"10.1006\/bbrc.1996.0140","article-title":"Expression and regulation by insulin of GLUT 3 in UMR 106-01, a clonal rat osteosarcoma cell line","volume":"218","author":"Thomas","year":"1996","journal-title":"Biochem. Biophys. Res. Commun."},{"issue":"1\u20132","key":"10.1016\/j.bone.2016.10.026_bb0185","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1007\/s11010-010-0634-z","article-title":"Stimulation of glucose transport in osteoblastic cells by parathyroid hormone and insulin-like growth factor I","volume":"348","author":"Zoidis","year":"2011","journal-title":"Mol. Cell. Biochem."},{"issue":"1","key":"10.1016\/j.bone.2016.10.026_bb0190","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0147391","article-title":"The effects of empagliflozin, an SGLT2 inhibitor, on pancreatic beta-cell mass and glucose homeostasis in type 1 diabetes","volume":"11","author":"Cheng","year":"2016","journal-title":"PLoS One"},{"issue":"3","key":"10.1016\/j.bone.2016.10.026_bb0195","doi-asserted-by":"crossref","first-page":"772","DOI":"10.1016\/j.bbrc.2015.10.109","article-title":"Protective effects of SGLT2 inhibitor luseogliflozin on pancreatic beta-cells in obese type 2 diabetic db\/db mice","volume":"470","author":"Okauchi","year":"2016","journal-title":"Biochem. Biophys. Res. Commun."},{"issue":"3","key":"10.1016\/j.bone.2016.10.026_bb0200","doi-asserted-by":"crossref","first-page":"519","DOI":"10.1111\/bph.12269","article-title":"Tofogliflozin, a novel sodium-glucose co-transporter 2 inhibitor, improves renal and pancreatic function in db\/db mice","volume":"170","author":"Nagata","year":"2013","journal-title":"Br. J. Pharmacol."},{"issue":"1","key":"10.1016\/j.bone.2016.10.026_bb0205","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1507\/endocrj.EJ14-0335","article-title":"Ameliorated pancreatic beta cell dysfunction in type 2 diabetic patients treated with a sodium-glucose cotransporter 2 inhibitor ipragliflozin","volume":"62","author":"Takahara","year":"2015","journal-title":"Endocr. J."},{"issue":"5","key":"10.1016\/j.bone.2016.10.026_bb0210","doi-asserted-by":"crossref","first-page":"891","DOI":"10.1007\/s00125-014-3196-x","article-title":"Canagliflozin, a sodium glucose co-transporter 2 inhibitor, improves model-based indices of beta cell function in patients with type 2 diabetes","volume":"57","author":"Polidori","year":"2014","journal-title":"Diabetologia"},{"issue":"3","key":"10.1016\/j.bone.2016.10.026_bb0215","doi-asserted-by":"crossref","first-page":"307","DOI":"10.1016\/8756-3282(95)00223-Z","article-title":"Differentiation of MC3T3-E1 osteoblasts is associated with temporal changes in the expression of IGF-I and IGFBPs","volume":"17","author":"Thrailkill","year":"1995","journal-title":"Bone"},{"issue":"4","key":"10.1016\/j.bone.2016.10.026_bb0220","doi-asserted-by":"crossref","first-page":"1516","DOI":"10.1172\/JCI117130","article-title":"Interleukin-11: A new cytokine critical for osteoclast development","volume":"93","author":"Girasole","year":"1994","journal-title":"J. Clin. Invest."},{"issue":"10","key":"10.1016\/j.bone.2016.10.026_bb0225","doi-asserted-by":"crossref","first-page":"1498","DOI":"10.1210\/me.2015-1133","article-title":"Sirtuin1 suppresses Osteoclastogenesis by Deacetylating FoxOs","volume":"29","author":"Kim","year":"2015","journal-title":"Mol. Endocrinol."},{"issue":"4","key":"10.1016\/j.bone.2016.10.026_bb0230","doi-asserted-by":"crossref","first-page":"1697","DOI":"10.1210\/en.2007-1408","article-title":"Runt-related transcription factor 2 (RUNX2) and RUNX2-related osteogenic genes are down-regulated throughout osteogenesis in type 1 diabetes mellitus","volume":"149","author":"Fowlkes","year":"2008","journal-title":"Endocrinology"}],"container-title":["Bone"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S8756328216303234?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S8756328216303234?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2024,6,20]],"date-time":"2024-06-20T07:05:50Z","timestamp":1718867150000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S8756328216303234"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,1]]},"references-count":46,"alternative-id":["S8756328216303234"],"URL":"https:\/\/doi.org\/10.1016\/j.bone.2016.10.026","relation":{},"ISSN":["8756-3282"],"issn-type":[{"value":"8756-3282","type":"print"}],"subject":[],"published":{"date-parts":[[2017,1]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"The impact of SGLT2 inhibitors, compared with insulin, on diabetic bone disease in a mouse model of type 1 diabetes","name":"articletitle","label":"Article Title"},{"value":"Bone","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.bone.2016.10.026","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2016 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}